HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

vasectrin II (VS II)

analog of porcine secretin with sequence intermediate between secretin & vasoactive intestinal peptide (VIP); structure in first source
Also Known As:
VS II; 4-Ala-5-Val-secretin; secretin, Ala(4)-Val(5)-; secretin, alanyl(4)-valine(5)-; Secretin, 4-L-alanine-5-L-valine-
Networked: 103 relevant articles (5 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Hata, Mitsumasa: 3 articles (06/2011 - 08/2008)
2. Minami, Kazutomo: 3 articles (06/2011 - 08/2008)
3. Sezai, Akira: 3 articles (06/2011 - 08/2008)
4. Yoshitake, Isamu: 2 articles (06/2011 - 01/2009)
5. Suzuki, Mitsunori: 2 articles (01/2009 - 08/2008)
6. Niino, Tetsuya: 2 articles (01/2009 - 08/2008)
7. Unosawa, Satoshi: 2 articles (01/2009 - 08/2008)
8. Nerdal, A: 1 article (12/2015)
9. Watfeh, R: 1 article (12/2015)
10. Baron, R: 1 article (12/2015)

Related Diseases

1. Neoplasms (Cancer)
2. Neoplasm Metastasis (Metastasis)
09/01/2004 - "Multivariate analyses identified an earlier primary tumor stage (I vs II) (P<.001), an absence of intervening stage III metastases (P =.02), solitary metastasis (P<.001), and a long (>36 months) disease-free interval from AJCC stage I or II to stage IV (P =.005) as predictive of survival. "
03/01/2014 - "In univariate analysis, stage (I vs II, III, IV), depth of tumor invasion (T1 vs T2, T3, T4), presence of lymph node metastasis and SUVmax (>5.74 vs ≤5.74) were significantly associated with recurrence. "
11/01/2006 - "HD was confirmed in 4 out of 6 cell lines and in 8 out of 34 (23.5%) RCC specimens, which correlated with the presence of metastasis, high tumor grade and had a tendency to more advanced stage (I vs. II-IV). "
09/01/1999 - "Cyclin D1 overexpression is significantly higher in patients with lymph node metastasis (50.0% vs 14.4%, P = 0.002) and with advanced pathological stages (I, 10%; II, 53.8%; IIIa, 41.7%, P = 0.048; stage I vs II, IIIa, P = 0.006). "
01/15/1998 - "All 244 patients were subdivided into three groups described as follows: score 1 and 2, group I; score 3 and 4, group II; score 5 and 6, group III. In univariate analysis, lower score groups had better overall survival rate (OS), disease-free survival rate (DFS), local control rate (LC), and distant metastasis-free rate (DMF) than higher score groups including groups I vs. II, II vs. III, or I vs. III. The differences were all statistically significant except for the difference of the DMF in group I vs. II. In multivariate analysis, score (range 1-6) was also statistically significant in OS (p < 0.0001), DFS (p = 0.0015), LC (p = 0.0032), and DMF (p = 0.0141). "
3. Lymphoma (Lymphomas)
4. Tick Infestations
5. Tachycardia (Tachyarrhythmias)

Related Drugs and Biologics

1. Permethrin (Ambush)
2. Glucagon (Glukagon)
3. vasectrin III
4. vasectrin I (VS I)
5. Cyclin D1
6. Lactic Acid
7. omega-N-Methylarginine (NG Monomethyl L Arginine)
8. Leukocyte Elastase (Neutrophil Elastase)
9. Messenger RNA (mRNA)
10. Pyridinolcarbamate (P23)

Related Therapies and Procedures

1. Lymph Node Excision (Lymph Node Dissection)
2. Transplants (Transplant)
3. Radiotherapy
4. Lasers (Laser)
5. Renal Dialysis (Hemodialysis)